GlassScriptPhysician profile
David I Sahar
NPI 1548245459
$2,968.95
in general payments reported to CMS, 2019-2025
28 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $203 · 2021: $519 · 2022: $497 · 2023: $564 · 2024: $363 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.54 | 2019-2025 | Jardiance, Cyltezo, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $239.34 | 2019-2025 | |
| Novo Nordisk INC | $222.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $203.43 | 2019-2021 | |
| Amgen INC. | $180.74 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $139.87 | 2019-2023 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $129.29 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $121.21 | 2022-2023 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.58 | 2019-2023 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $101.62 | 2025 | Amvuttra |
| Philips North America LLC | $98.00 | 2025 | US Eq Undivided |
| Sanofi-Aventis U.S. LLC | $95.66 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $93.72 | 2020-2023 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $81.23 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $52.75 | 2023-2024 | Farxiga |
| Janssen Biotech, INC. | $51.22 | 2023-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $48.76 | 2023-2024 | Ibsrela |
| Amarin Pharma, INC. | $36.82 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $33.16 | 2023 | Arcalyst |
| Coala Life INC | $32.11 | 2021 | |
| Abbvie INC. | $28.78 | 2024 | |
| Lilly USA, LLC | $25.39 | 2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $25.37 | 2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $22.84 | 2019 | |
| Intercept Pharmaceuticals, INC. | $20.90 | 2024 | |
| Mylan Specialty L.P. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.